Clinical Trial Update: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating aflibercept (Eylea) for efficacy in Type 3 choroidal neovascularization has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Type 3 Choroidal Neovascularization

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Type 3 Choroidal Neovascularization | Phase 4 | Status: COMPLETED